ABSTRACT
Topical timolol and lasers are widely used for the treatment of infantile hemangioma (IH), and they can replace propranolol as the first-line treatment of IH. We aimed to investigate the efficacy and safety of topical timolol alone or lasers plus topical timolol versus lasers alone for the treatment of IH using a meta-analysis. We searched the PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases. A more conservative random effect model meta-analysis technique was used to analyze the efficacy and adverse reactions of timolol and lasers. Ten RCTs with a total of 979 patients with IH were included in this meta-analysis. Treatment with topical timolol alone was as effective as lasers in treating IH (risk ratio [RR] = 0.99, p = 0.94), with similar adverse events. The difference was not statistically significant (RR = 1.67, p = 0.14). Combined treatment with topical timolol and lasers showed a favorable response rate compared with treatment with either lasers (RR = 1.23, p = 0.01) or topical timolol (RR = 1.35, p = 0.001) alone. Furthermore, compared to topical timolol alone, the combined treatment indicated similar risks of adverse events (RR = 0.70, p = 0.38) but fewer risks of adverse events (RR = 0.39, p = 0.004) compared to lasers alone. This meta-analysis provided evidences that a combined treatment with topical timolol and lasers might be more effective than a single treatment strategy in infants with IH, and with no significant increase in adverse reactions. The combination of topical timolol and laser therapy might be the preferred choice for the treatment of IHs.
Subject(s)
Hemangioma , Skin Neoplasms , Humans , Infant , Administration, Topical , Adrenergic beta-Antagonists/adverse effects , Hemangioma/drug therapy , Lasers/adverse effects , Propranolol , Skin Neoplasms/drug therapy , Skin Neoplasms/chemically induced , Timolol/adverse effects , Treatment Outcome , Combined Modality Therapy/adverse effectsABSTRACT
Here, we describe the first complete mitochondrial genome of Yao silkworm, a unique silkworm resource native at Guangxi, China. This circular molecule is 15,656 bp long and contains the typical set of 37 genes (13 protein-coding genes, two ribosomal RNA genes, and 22 transfer RNA genes) and one non-coding A + T-rich region of 494 bp long. The genome organization and gene arrangement are identical to those observed in all available Bombyx mori strains. The phylogenetic tree inferred from Bayesian inference provides a molecular evidence that Yao silkworm belongs to the domestic silkworm (B. mori), rather than a novel silkworm species.
